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First described in 2004, endometrial stem cells (EnSCs) are adult stem cells isolated from the endometrial tissue.
EnSCs comprise of a population of epithelial stem cells, mesenchymal stem cells, and side population stem cells. When
secreted in the menstrual blood, they are termed menstrual stem cells or endometrial regenerative cells. Mounting
evidence suggests that EnSCs can be utilized in regenerative medicine. EnSCs can be used as immuno-modulatory
agents to attenuate inflammation, are implicated in angiogenesis and vascularization during tissue regeneration, and
can also be reprogrammed into induced pluripotent stem cells. Furthermore, EnSCs can be used in tissue engineering
applications and there are several clinical trials currently in place to ascertain the therapeutic potential of EnSCs.
This review highlights the progress made in EnSC research, describing their mesodermal, ectodermal, and endodermal
potentials both in vitro and in vivo.
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Cells in the earliest developmental stages in the embryo
can generate embryonic and extra-embryonic tissues [1].
The ability to generate other cell types is known as po-
tency. In the inner cell mass of the blastocyst in the em-
bryo, the cells pluripotent, meaning they can give rise to
the ectoderm, mesoderm, and endoderm lineages (entire
organism). Pluripotent stem cells include embryonic
stem cells (ESCs) from the inner cell mass of blastocysts,
epiblast derived stem cells from embryos after implant-
ation, embryonic germ cells (EGCs) from primordial germ
cells, embryonic carcinoma cells (ECCs) derived from
germ cells tumors, and germ line stem cells from testicu-
lar tissue [2-4]. As the reproductive cycle progresses, cell
potency decreases and only a small fraction of cells retain
their potency, namely adult stem and progenitor cells.
These are limited to tissue generation within specific line-
ages. Adult stem cells (ASCs) are found in numerous hu-
man tissues including: intestines [5], muscles [6], skin [7],
blood [8], nervous system [9-11], endometrium [12],
heart, liver [13,14], dental pulp, adipose tissue, synovial
membrane, umbilical cord blood, amniotic fluid [15,16],* Correspondence: a.seifalian@ucl.ac.uk
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stem cells, ASCs are considered safer for therapeutic pur-
poses and several are currently used in clinical trials. The
concept of using ASCs over embryonic stem (ES) cells in
regenerative medicine has recently gained traction. The
rationale for this trend include: (1) The complicated con-
trol of the culture conditions of ESCs; (2) the existence of
several intermediate stages before reaching terminal differ-
entiation of ESCs; (3) Teratoma formation is a major obs-
tacle for clinical development of ESCs; (4) immunological
rejection of cells derived from ES cells to the recipient and
(5) ethical scrutiny involved in ESCs application.Endometrium and endometrial stem cells (EnSCs)
The human endometrium is an extraordinary model of
controlled tissue remodeling, unparalleled in other or-
gans, which grows about 7 mm within one week in every
menstrual cycle [18]. At this rate, there is a very rapid
rate of angiogenesis for approximately 500 cycles within
a tightly controlled manner in a woman’s lifetime. The
human endometrium, derived from the mucosal lining
of the fused paramesonephric tubes during embryogen-
esis, is a dynamic tissue (Figure 1). It is comprised of
two major zones: (1) the functionalis, a transient layer
containing glands extending from the surface epithelium
as well as the supportive stroma, and (2) the basalis,
comprised of the basal region of the glands, stroma,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The endometrium. Location of endometrial stem cells in human endometrium. In human endometrium, epithelial progenitor cells are
located in the base of the glands in the basalis, while endometrial stem cells are located near blood vessels even in functionalis.
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genitor cells are located in the basal layer (Figure 1) of
human endometrium [19]. These rapidly proliferating
cells (transient cells) then move to the functional layer
[20] and actively participate in the regeneration and re-
modeling of the endometrium. Endometrial mesenchy-
mal stem cells (MSCs) have been identified in the
endometrium (lining of the uterus). Indeed, cloning of
human endometrial cells confirmed the existence of
endometrial epithelial progenitor cells for the first time
in 2004 [21]. There are three distinct endometrial stem
cells including: epithelial progenitor cells, MSCs and
endothelial progenitor cells [22]. Recent studies reported
the isolation of multipotent EnSCs from menstrual
blood [23,24] or endometrial biopsies [25]. These cells
are called endometrial regenerative cells (ERCs), and are
heterogenic and have morphological differences among
their different isolation sites. Stromal cells have been
cultured from menstrual blood [24,26], suggesting that
endometrial MSCs are shed during menstruation [22]
but epithelial cells have not been detected [27], suggest-
ing that epithelial progenitors may not be shed during
menstruation and more likely reside in the basalis. Dur-
ing the proliferative menstrual phase, the endometrium
prepares for recruiting new EnSCs to cover the new
blood vessels. The variation in the numbers of endothe-
lial progenitor cells and stem cell derived factor-1 is a
pivotal factor for release and homing of stem cells [28].These EnSCs have properties similar to bone marrow or
adipose tissue stem cells. They proliferate and differentiate
throughout the estrous cycle and during pregnancy under
the control of the ovarian hormones. Clonogenic MSCs
are responsible for regenerating the endometrium, and
they exist in peri-menopausal women, postmenopausal
women, and women on oral contraceptives [29]. Irregular
function of these SCs may contribute to the pathogenesis
of endometriosis and the growth of tissue outside the
uterine cavity, causing dysmenorrhoea, subfertility and
endometrial carcinoma [30]. Stem cells that are ectopically
distributed through lymphovascular metastasis [31] may
also contribute to the pathogenetic process, because their
high proliferation promotes rapid clonal expansion [32].
The progenitor cells in the endometrium has a high
proliferative potential that can generate 6 × 1011 cells
from a single cell, with the ability to differentiate into
large cytokeratin-expressing structures when cultured in
Matrigel [17], comprising laminin, collagen IV and hepa-
ran sulfate proteoglycan. It was used instead of mouse
embryonic fibroblast feeder layers for ES cells prolifera-
tion. Our data shows that mesenchymal stem cells from
endometrium can be grown extensively both in vivo and
in vitro. These cells are not tumorigenic in nude mice
and could be passaged approximately 40 times in vitro.
The fact that about 600,000 hysterectomies are per-
formed yearly in the United States creates a potential
source of endometrial cells [33]. Studies have indicated
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endometrial biopsy [34,35]. Indeed, endometrial biopsies
may represent a viable technique in harvesting EnSCs,
as they are routinely performed for gynecologic pur-
poses, and does not impair endometrial function. Thus,
endometrial tissue specimens from women who are not
receiving hormonal therapy are suitable for isolation of
stem cells (Figure 2).
Endometrial stem cells may be derived from fetal stem
cells or bone marrow stem cells, including haemopoietic
SCs, MSCs and endothelial progenitor cells [36-38]. The
human endometrium shows expression of the pluripo-
tency factors Sox-2, Oct-4 and Nanog. Sox-2 co-localized
with telomerase, contribute to the immortality of embry-
onic stem cells [39]. Reprogramming of differentiated cells
to an induced pluripotent stem (iPS) cell is through induc-
tion or increasing in the expression of Oct-4, Sox-2, Klf-4,
and c-Myc [40] that easily could be achieved from EnSCs
that already express these factors. As a result, iPS cells
from EnSCs have been established as early as 12 days after
transduction rather than the usually reported 4 weeks
for other cell types [41]. As patient- or disease-specific
biomedical research using iPS cells becomes more
widespread, the endometrium may play a key role as re-
programmable cells into donor- or disease-specific pluri-
potent cell lines for the female population.
Markers of human EnSCs
Flow cytometric analysis of important endometrial stem
cell markers are indicated in Figure 3. Cultured EnSCsFigure 2 The endometrial stem cell isolation. A diagram that shows the
then serial filtration through 70 μm and 40 μm meshes, ficoll separation anexpress typical markers used for bone marrow stem cells;
CD9, CD13, CD14, CD29, CD31, CD44, CD73, CD90,
CD105, CD117, CD133, CD146 [42], but not STRO-1,
CD31 (endothelial) and CD34 (haemopoietic stem cell
and endothelial) [43]. The EnSCs could be purified on the
basis of their co-expression of two perivascular markers
CD140b and CD146 [44]. Cells with a hematopoietic stem
cell phenotype (CD34 + CD45+) co-expressing CD7 and
CD56 have been identified in human endometrial cell sus-
pensions and may be lymphoid progenitors [45]. Musashi-
1, an RNA-binding protein in neural stem cells and
an epithelial progenitor cell marker that regulates self-
renewal signaling pathways, has been recognized in hu-
man endometrium. NAC1 is a transcription repressor that
is involved in self-renewal and the maintenance of pluri-
potency in embryonic stem cells [46]. Ishikawa et al. dem-
onstrated that NAC1 was over-expressed in the normal
cyclic endometrium in the early and mid proliferative
phases [47]. MSI1 and NOTCH1, which maintain SCs in
an undifferentiated state, are expressed in EnSCs. Tissue
non-specific alkaline phosphatase, also immune-localizes
to a perivascular location in human endometrium and
may be useful for the prospective isolation of EnSCs [48].
Leucine rich repeat containing G protein-coupled
receptor-5 (Lgr-5) is also expressed in human endometrial
epithelial progenitor cells and endometrial [49] stromal
cells [50]. W5C5 is a single marker for purifying EnSC,
which differentiates into adipogenic, osteogenic, chondro-
genic, and myogenic cell lineages [51]. One-third of these
EnSCs expressed α-smooth muscle actin (αSMA) but notstepwise isolation of endometrial stem cells by collagenase digestion,
d selection the colony forming cells.
Figure 3 Flow-cytometric analysis of endometrial stem cell markers. Further phenotypic analysis of EnSCs after enrichment in culture.
Expression of Oct4, CD90, CD105, CD146 and CD44 have more percentage of EnSC markers.
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cells and that they occupy a peri-vascular niche.
Immunogenicity of EnSCs
Utilizing ES cells in regenerative therapy is associated
with many hazards. Without adequate ES cells screening
procedures, patients would face tissue rejection similar
as rejection of organ transplants. A solution to this
problem is to create patient specific stem cells. Unlike
ES cells, adult stem cells are not rejected by the immune
system [52]. The human endometrium has unique im-
munological requirements. In pregnancy, the endomet-
rium must tolerate the invading embryo, which expresses
both paternal and maternal antigens. In 2012, Peron et al.
demonstrated that endometrial MSCs were able to sup-
press neuro-inflammation in a mouse model of multiple
sclerosis. This suppression is dependent on the secretion
of anti-inflammatory cytokines such as IL-10 and IL-27,
and also the expression of indoleamine-2,3-dioxigenase[53]. Menstrual blood SCs were tested for allogeneic re-
sponse in culture with peripheral blood mononuclear cells
(PBMN). The SCs were analyzed at a 1:2 stimulator (mito-
mycin C treated PBMN) to responder cell (menstrual
blood SCs) ratio for 6 days. The menstrual blood SCs
demonstrated a moderately weak stimulatory response in
a mixed lymphocyte reaction (MLR). An emerging bank
of data allows for the classification of the mesenchymal
stem cell from bone marrow as immunosuppressive cell
source derived from studies with human cells [54,55].
Some studies support that SC administration is a potential
way to suppress tumor growth. It has been demonstrated
that human skin-derived progenitor cells have selective
tropism for malignant tissues. Also more interestingly,
these cells have the ability to inhibit tumor growth [56].
MSCs could selectively integrate into gliomas after intra-
vascular or local delivery [57-59]. ERC administration
inhibits C6 tumor growth and its administration associ-
ated with reduced neovascularization [60]. Despite the
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model, these data support a paradoxical tumor inhibi-
tory activity of ERC. Further studies are needed to de-
termine the qualitative differences between physiological
angiogenesis, which seems to be supported by ERC and
tumor angiogenesis which appeared to be inhibited.
Other studies have demonstrated that MSCs directly se-
crete tumor inhibitory factors [61,62].
Potency and differentiation of EnSCs
The main features of mesenchymal stem cells are their
ability for self-renewal, colony-forming ability, and dif-
ferentiation into mesoderm-derived lineages including
adipogenic, chondrogenic and osteogenic differentiation
[63-65]. Endometrial SCs that are persistent in the uter-
ine endometrium from the fetal to the postmenopausal
period [66] were found to differentiate into adipocytes,
osteoblasts and chondrocytes as well [67,68] (Figure 4).
The modulation of p38 and c-jun might play an import-
ant role for the differentiation and proliferation of nor-
mal human endometrial cells [69]. These differentiations
can identify by positive staining, with Oil Red O (for
lipid droplets), alizarin red (for osteogenesis), von KossaFigure 4 Multipotent differentiation of endometrial stem cells. Endom
as described in box1-15 and assessed for differentiation using the indicated
lipid vacuoles stained by Oil-Red. B) Osteocytic differentiation, red indicates c
differentiated from EnSCs. D) Chondrocytic differentiation, the blue color resu
conjugated mAb indicates pre-neural marker Nestin stain. F) Angiogenesis of
the red conjugated mAb indicates receptor interacting protein (RIP). H) Hepat
differentiation, red indicates α-actinin stain.(for calcified extracellular matrix), and Alcian blue (for
sulfated proteoglycans), respectively. Clonogenicity of
EnSCs does not vary from the proliferative to secretory
stage of the menstrual cycle, or between active, cycling
and inactive endometrium for both epithelial and stro-
mal cells [29].
Identification and isolation of differentiated cells
Research pertaining to stem cell biology in the female re-
productive tract is still in its infancy, and although surface
markers of prospective isolation of human endometrial
stromal colony-forming cells (putative endometrial stro-
mal/progenitor cells) have recently identified [17,44], there
remains a need for definitive markers of both myometrial
and endometrial stem cells for more selective isolation
and enrichment. Complete characterization of uterine
stem/ progenitor cells will improve our understanding of
the mechanisms supporting physiological regeneration of
the female reproductive tract. In addition, such studies
will enhance our understanding of uterine cancer, hyper-
plasia, endometriosis, leiomyomas and adenomyosis. In-
deed, our data and the published observations from
other laboratories have enabled us to propose a noveletrial stem cells were cultured under appropriate differentiation media
staining methods. A) Adipocytic differentiation, the red color indicates
alcium stained by Alizarin Red and C) Von-Kossa staining of osteoclasts
lted from Alcian blue staining. E) Neuronal differentiation, the red
EnSCs, the green indicated CD31 stain. G) Oligodendrocytic differentiation,
ocytic differentiation, green indicates albumin stain. I) Myocytic
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regeneration. Finally, availability of these stem cells sug-
gests new approaches to reconstruction of the human
uterus and perhaps other organs as well.
The final step for processing stem cells before trans-
plantation would be the identification and isolation of the
differentiated cells. Recognition and selection of desired
cells can be done via reverse transcriptase polymerase
chain reaction, flow cytometry or fluorescence-activated
cell sorting (FACS). Unfortunately, these methods would
destroy many of the differentiated cells, thereby rendering
them unusable. Also, flow cytometry and FACS is de-
pendent on the presence of specific markers on the cell
surface, which are not always displayed on every type of
differentiated cells [70]. Thus, a more viable technique for
identification of differentiated cells can be made with the
transient transfection of a reporter gene into a stem cell
source. The reporter gene can encode a fluorescent (green
fluorescent protein) or a drug selectable protein. The transi-
ent transfection would be favorable for human cell therapy
because the reporter is only meant for selection purposes.
Comparison between EnSCs, MSCs, and umbilical cord
blood stem cells
Genetic profiling of EnSCs and bone marrow MSCs re-
vealed that they had similar (although not identical)
cytokine production, miRNAs, and gene expression [71].
It was reported that EnSCs express higher levels of
ICAM-1 and IL-8, while bone marrow MSCs express
higher levels of TGFβ1, TGFβ2, IL-6, and vascular endo-
thelial growth factor (VEGF). This observation suggests
that EnSCs may play a role in acute inflammation, and
may be more suitable for tissue engineering applications.
It was also reported that, compared to MSCs, EnSCs
had a 27-fold higher level of PDGF-BB, and 14-fold
higher level of angiopoietin. This indicates that EnSCs
may activate alternative angiogenesis pathways. However,
more studies are required to ascertain if EnSCs stimulate
higher levels of angiogenesis than bone marrow MSCs
in vivo. It was shown that EnSCs produced collagen type
II and proteoglycans when cultured on nanofibrous
polycaprolactone material, suggesting their cartilaginous
tissue differentiation potential [72]. It was also observed
that proliferation of EnSCs was faster than bone marrow
MSCs, and EnSCs express the pluripotency marker
OCT-4, but lack the MSC marker STRO1 [72]. Umbilical
cord blood was first used in bone marrow transplant in
a patient with Fanconi’s anaemia in 1988 [73]. Consider-
ing that a large proportion of haematopoietic stem cells
are found in the fetal circulation, there is also a corres-
pondingly large proportion of haematopoietic stem cells
in the umbilical cord. Bone marrow MSCs are distinct
from haematopoietic stem cells, as they are CD45−. Ma-
ture bone marrow MSCs are a heterogeneous populationof cells that are able to support haematopoiesis, and cap-
able of differentiating into different lineages such as
neural cells [74,75], muscle [76-78], liver cells [79,80],
among many others. Various studies have reported that
a single mesenchymal progenitor cell is responsible for
all lineages are produced from bone marrow MSC
in vitro. It has been shown that bone marrow MSCs
contain more mesenchymal progenitor cells when com-
pared to umbilical cord blood stem cells. Indeed, the
proportion of MSCs within umbilical cord blood is ex-
tremely low and difficult to detect [81]. Nevertheless,
more studies comparing EnSCs, MSCs and umbilical
cord blood stem cells are required to accurately ascertain
their similarities and differences.
EnSCs in regenerative therapeutics
To date, EnSCs have been used in several pre-clinical
and small animal studies. The regenerative potential of
EnSCs was first seen in an experimental model of Du-
chenne muscular dystrophy in immunodeficient mdx
mice, whereby EnSCs that were transplanted into atro-
phied skeletal muscle fibres contributed to muscle repair
[26]. Although the exact mechanism of repair has not
been elucidated, it was postulated that cell fusion and in
situ differentiation might have been involved, in part due
to the observation that the transplanted EnSCs homed
to peri-muscle fibre regions and promoted angiogenesis.
The concept of angiogenesis was also supported by an-
other study, where EnSCs were improved critical limb is-
chaemia induced by femoral artery ligation [82].
The use of EnSCs to treat myocardial infarction in a
murine model was also seen. In this study, EGFP-labelled
EnSCs were grafted into the infarct area of nude rat
hearts, which subsequently differentiated into α-actinin+,
troponin+ striated cardiac muscle cells [83]. Furthermore,
it was observed that a significantly larger reduction in in-
farct area was seen in animals treated with EnSCs, com-
pared to control bone marrow MSCs.
Gargett et al., the first group that reported the existence
of EnSCs in 2004 [21], are currently developing an autolo-
gous tissue engineered scaffold using artificial meshes and
EnSCs for the treatment of pelvic organ prolapse, and was
tested in vivo, on an animal skin wound repair model
[84,85]. Results indicated that EnSCs promoted neovascu-
larization, increased tissue integration, reduced chronic
inflammation, increased deposition of collagen fibres and
distensibility of the mesh at 3 months post-implantation.
They also found that EnSCs downregulated foreign body
reactions and enhanced mesh integration, indicating they
have a role to play in modulating tissue response with
regards to implanted foreign materials.
Our group has also advocated the tissue engineering
approach to the application of EnSCs. To this end, we
have fabricated nanofibrous silk-collagen fibres that were
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bladder wall for women [86]. We had also shown that
EnSCs were capable of differentiating into smooth
muscle cells [86], potentially functioning as an autolo-
gous cell source for bladder tissue engineering.
Intraperitoneal delivery of EnSCs were also studied in
a murine model of encephalomyelitis [53]. It was founds
that EnSCs exerted a an anti-inflammatory effect, as evi-
denced by a lower number of infiltrating mononuclear
cells in the lesions, upregulation of IL-10 and IL-27 in
the spleen, and reduced recruitment of Th1 and Th17
cells in the central nervous system.
EnSCs were also used to demonstrate neural regenera-
tive capabilities, whereby reduced neuronal cell death
was seen when oxygen-deprived primary neuronal cell
cultures were exposed to EnSCs [87]. It was also ob-
served that EnSCs released neuroprotective trophic
factors such as neurotrophin-3 (NT-3), brain-derived
neurotrophic factor (BDNF), and VEGF. The in vivo part
of the study was done in a murine model of ischaemic
stroke, whereby injection of EnSCs resulted in signifi-
cantly lower histological and behavioural impairments. It
was reported that EnSCs exerted a trophic effect, releas-
ing factors that promoted survival of neural cells.
The use of EnSCs to treat glioma was observed in a
murine model. In this study, EnSCs were administered
intravenously in a murine model of intracranial glioma.
Results revealed a reduction of tumour size of almost
50%, possibly due to its anti-angiogenic effects [60].
The applications of EnSCs have also been reported in
several human studies. The first reported use of EnSCs
was demonstrated by Zhong et al. [88]. Clinical-grade
menstrual blood-derived EnSCs have been used in a small
Phase I clinical trial of 4 patients suffering from multiple
sclerosis, whereby EnSCs were delivered via intravenous
and intrathecal routes. Results showed no immunological
reactions or adverse side effects after 1 year [88].
Another human study involved a patient suffering
from Duchenne muscular dystrophy that was given
intramuscular injections of EnSCs. Follow-up observa-
tions reported no adverse effects even after 3 years, and
increased muscle strength and decreased respiratory in-
fections was also reported [89].
The third reported use of EnSCs in human was a pa-
tient with congestive heart failure, who was given intra-
venous administration of EnSCs. Results revealved that
ejection fraction of the patient increased from 30% to
40%, decreased basic natriuretic peptide values (Pro-
BNP), and decreased Minnesota Living with Heart Fail-
ure Questionnaire score at 1-year follow up [90].
The promise and limitations of EnSCs
EnSCs are an attractive source of stem cells for regen-
erative therapeutics as they are easily obtainable andeasily expandable in culture, as has been demonstrated
to be safe for clinical use. Protocols and methods for
extraction and isolation of EnSCs are well established, as
purified EnSCs can be obtained using magnetic bead
sorting using the W5C5/SUSD2 marker. In addition,
clinical-grade good manufacturing practice (cGMP) are
currently being developed for culture expansion of
EnSCs, and have been tested in animals. However, there
is a lack of published information on the exact cGMP
protocols in place for the production of EnSCs. This is
compounded by the fact that there is no general scien-
tific consensus regarding specific MSC markers to detect
EnSCs; rather, researchers rely on the ability of MSCs to
adhere to plastic. Hence, the purity of EnSCs is not
guaranteed as the cultures could potentially contain
fibroblasts.
EnSCs can be obtained from menstrual blood; hence
no invasive procedures are needed to harvest these cells.
A menstrual cup is used to collect menstrual blood over
several hours on days 2 to 3 of the menstrual period. Al-
though there is a potential risk of infection via vaginal
contact, there have been no reports of any complications
after antibiotic use.
Although the ability of EnSCs to re-integrate into tis-
sue in vivo has been demonstrated, there is a theoretical
risk that endometriosis could develop from using EnSCs.
However, none of the animal model studies have reported
this. Nevertheless, it is an aspect of EnSC application that
warrants attention. Indeed, transdifferentiation (some-
times referred to as adult stem cell plasticity) is a contro-
versial topic in the field of stem cells. It is highly probable
that nuclear reprogramming and altered transcriptional
activity of important developmental genes are in part re-
sponsible for transdifferentiation. Transdifferentiation can
be seen as a form of metaplasia due to alterations in the
extracellular environment, and often happens during tis-
sue damage [91]. Hence, one probable cause of endomet-
riosis is thought to be due to metaplasia of the peritoneal
lining. However, there is also evidence to suggest that
circulating stem cells can be a source of metaplastic trans-
differentiation when it gains access into the pelvic cavity.
Genetically-tagged bone marrow MSCs were tracked in a
murine transplant model, and it was established that a
small population of it integrated into endometriosis le-
sions and transdifferentiated into stromal cells (0.1%) and
epithelial cells (<0.04%) [92]. It was found that these bone
marrow MSCs contributed to the progression of endomet-
riosis rather than initiating it [93]. Changes in cellular
phenotype may involve processes that are associated with
both embryogenesis and carcinogenesis, such as mesen-
chymal epithelial transition (MET) and epithelial mesen-
chymal transition (EMT) [94]. Correspondingly, the
invasiveness of endometriotic cells may be attributed to
the changes in cellular phenotype in endometriotic lesions.
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E-Cadherin- stromal cells, and an invasive CK+E-Cad-
herin−N-Cadherin+ epithelial cells (similar to carcinoma
micrometastasis) are found in endometriotic lesions [95].
In line with carcinoma characteristics, a regression of
endometriotic lesion is seen in estrogen depletion therapy,
but recur when therapy stops. This indicates that a quies-
cent stem cell population is present within the lesion,
which reactivates on exposure to estrogen. Thus it may
also follow that EnSCs within lesions may also contribute
to subsequent lesions.
In terms of regenerative medicine applications, it is
envisioned that bone marrow MSCs are more suited for
osteogenic differentiation and therefore used for bone
tissue engineering, while EnSCs are more suited for soft
tissue engineering, such as bladder reconstruction. Due
to the intense interest generated with using EnSCs for
regenerative medicine, we believe that EnSCs were intro-
duced too quickly into human tests without adequately
assessing its impact on large animal models. Further-
more, the exact mechanism of how EnSCs exert is re-
generative potential is not clearly understood. Hence
more robust large animal studies are needed to fill this
information gap that currently exists.
Concluding remarks and future perspectives
Although EnSCs would form a non-invasive and steady
supply of autologous stem cells for women, we must not
forget that this means that 50% of the population (i.e.
the male population) is excluded. Furthermore, non-
invasive harvesting of EnSCs would not be possible from
post-menopausal women (in this case, endometrial bi-
opsy might be possible, but data regarding the potency
of EnSCs in post-menopausal women has not been pub-
lished). In addition, the issue of EnSCs storage could
also develop into the same debates we are facing regard-
ing the storage of cord blood; is there enough scientific
evidence to justify storage of EnSCs for future use?
Nevertheless, given the significant progress made in the
application of EnSCs in regenerative medicine, it is envi-
sioned that human clinical trials would be conducted in
the near future. Indeed, the RECOVER-ERC trial was re-
cently launched by Medistem Inc (a start-up company
based in San Diego, California), which aims to evaluate
the potency of EnSCs in 60 heart failure patients in a
double-blind placebo controlled Phase II clinical trial [96].
Furthermore, a search in the clinicaltrials.gov database re-
veals that several clinical trials regarding EnSCs are under-
way, with applications ranging from treating critical limb
ischaemia (NCT 01558908), liver cirrhosis (NCT01483248),
type I diabetes (NCT01496339), and in vitro fertilization
(NCT01649752). Hence, it can be envisioned that data
from human patients would be available in due course to
evaluate the clinical impact of EnSCs.In conclusion, the discovery of EnSCs represents a
paradigm shift for the use of adult stem cells by offering
an “off the shelf” therapeutic application regenerative
medicine. The EnSCs niche and in situ role highlight
these cells as being important for cell and tissue regener-
ation. This work highlights crucial features of an inter-
esting population of mesenchymal progenitors isolated
form endometrial tissue. Cells grown in vitro were char-
acterized by a high clonogenic potential and a long-term
survival. Advantages in comparison with MSC from
other sources include a greater ease of supply and the
protracted availability during a woman’s lifetime with
the additional benefit of deriving stem cells from a waste
tissue, thus avoiding critical ethical issues.
In the light of their capacity to differentiate into mes-
enchymal tissues and their propensity to undergo gen-
etic manipulation, EnSCs hold considerable promise for
novel therapeutic approaches for diseases in the wider
field of regenerative medicine.
Competing interests
The authors declare that no competing interests exist.
Authors’ contributions
JV, AT, AS, AMS conceived and planned the structure of the manuscript. JV,
AT, AS, AMS collated and analyzed the data. JV, AT, AS, AMS wrote the
manuscript. All authors read and approved the final manuscript.
Author details
1Centre for Nanotechnology and Regenerative Medicine, UCL Division of
Surgery & Interventional Science, University College London (UCL), London
NW3 2QG, UK. 2Applied Cell Sciences Department, School of Advanced
Technologies in Medicine, Tehran University of Medical Sciences, Tehran,
Iran. 3UCL Medical School, University College London (UCL), London, UK.
4Royal Free London NHS Foundation Trust Hospital, London, UK.
Received: 5 April 2014 Accepted: 30 June 2014
Published: 1 August 2014
References
1. Kelly SJ: Studies of the developmental potential of 4‐and 8‐cell stage
mouse blastomeres. J Exp Zool 1977, 200(3):365–376.
2. Conrad S, Renninger M, Hennenlotter J, Wiesner T, Just L, Bonin M, Aicher
W, Bühring H-J, Mattheus U, Mack A: Generation of pluripotent stem cells
from adult human testis. Nature 2008, 456(7220):344–349.
3. Ko K, Araúzo-Bravo MJ, Tapia N, Kim J, Lin Q, Bernemann C, Han DW,
Gentile L, Reinhardt P, Greber B: Human adult germline stem cells in
question. Nature 2010, 465(7301):E1–E1.
4. Stadtfeld M, Hochedlinger K: Induced pluripotency: history, mechanisms,
and applications. Genes Dev 2010, 24(20):2239–2263.
5. Bjerknes M, Cheng H: Clonal analysis of mouse intestinal epithelial
progenitors. Gastroenterology 1999, 116(1):7–14.
6. Jankowski R, Deasy B, Huard J: Muscle-derived stem cells. Gene Ther 2002,
9(10):642–647.
7. Alonso L, Fuchs E: Stem cells of the skin epithelium. Proc Natl Acad Sci U S A
2003, 100(Suppl 1):11830–11835.
8. Spangrude GJ, Smith L, Uchida N, Ikuta K, Heimfeld S, Friedman J, Weissman
I: Mouse hematopoietic stem cells. Blood 1991, 78(6):1395–1402.
9. Morrison SJ, White PM, Zock C, Anderson DJ: Prospective identification,
isolation by flow cytometry, and in vivo self-renewal of multipotent
mammalian neural crest stem cells. Cell 1999, 96(5):737–749.
10. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS,
Gage FH, Weissman IL: Direct isolation of human central nervous system
stem cells. Proc Natl Acad Sci U S A 2000, 97(26):14720–14725.
Verdi et al. Journal of Biological Engineering 2014, 8:20 Page 9 of 10
http://www.jbioleng.org/content/8/1/2011. Rietze RL, Valcanis H, Brooker GF, Thomas T, Voss AK, Bartlett PF:
Purification of a pluripotent neural stem cell from the adult mouse
brain. Nature 2001, 412(6848):736–739.
12. Chan RW, Gargett CE: Identification of Label‐Retaining Cells in Mouse
Endometrium. Stem Cells 2006, 24(6):1529–1538.
13. Beltrami AP, Cesselli D, Bergamin N, Marcon P, Rigo S, Puppato E, D’Aurizio
F, Verardo R, Piazza S, Pignatelli A: Multipotent cells can be generated
in vitro from several adult human organs (heart, liver, and bone
marrow). Blood 2007, 110(9):3438–3446.
14. Crisan M, Yap S, Casteilla L, Chen C-W, Corselli M, Park TS, Andriolo G, Sun B,
Zheng B, Zhang L: A perivascular origin for mesenchymal stem cells in
multiple human organs. Cell Stem Cell 2008, 3(3):301–313.
15. da Silva ML, Chagastelles PC, Nardi NB: Mesenchymal stem cells reside in
virtually all post-natal organs and tissues. J Cell Sci 2006,
119(11):2204–2213.
16. Kalervo Väänänen H: Mesenchymal stem cells. Ann Med 2005, 37(7):469–479.
17. Gargett CE, Schwab KE, Zillwood RM, Nguyen HP, Wu D: Isolation and
culture of epithelial progenitors and mesenchymal stem cells from
human endometrium. Biol Reprod 2009, 80(6):1136–1145.
18. McLennan CE, Rydell AH: Extent of endometrial shedding during normal
menstruation. Obstet Gynecol 1965, 26(5):605–621.
19. Padykula HA: Regeneration in the primate uterus: the role of stem cells.
Ann NY Acad Sci 1991, 622:47–56.
20. Okulicz WC, Ace CI, Scarrell R: Zonal changes in proliferation in the rhesus
endometrium during the late secretory phase and menses. Exp Biol Med
1997, 214(2):132–138.
21. Chan RW, Schwab KE, Gargett CE: Clonogenicity of human endometrial
epithelial and stromal cells. Biol Reprod 2004, 70(6):1738–1750.
22. Gargett CE, Masuda H: Adult stem cells in the endometrium. Mol Hum
Reprod 2010, 16(11):818–834.
23. Meng X, Ichim TE, Zhong J, Rogers A, Yin Z, Jackson J, Wang H, Ge W,
Bogin V, Chan KW: Endometrial regenerative cells: a novel stem cell
population. J Transl Med 2007, 5(1):57.
24. Patel AN, Park E, Kuzman M, Benetti F, Silva FJ, Allickson JG: Multipotent
menstrual blood stromal stem cells: isolation, characterization, and
differentiation. Cell Transplant 2008, 17(3):303–311.
25. Schüring AN, Schulte N, Kelsch R, Röpke A, Kiesel L, Götte M:
Characterization of endometrial mesenchymal stem-like cells obtained
by endometrial biopsy during routine diagnostics. Fertil Steril 2011,
95(1):423–426.
26. Cui CH, Uyama T, Miyado K, Terai M, Kyo S, Kiyono T, Umezawa A:
Menstrual blood-derived cells confer human dystrophin expression in
the murine model of Duchenne muscular dystrophy via cell fusion and
myogenic transdifferentiation. Mol Biol Cell 2007, 18(5):1586–1594.
27. Musina R, Belyavski A, Tarusova O, Solovyova E, Sukhikh G: Endometrial
mesenchymal stem cells isolated from the menstrual blood. Bull Exp Biol
Med 2008, 145(4):539–543.
28. Elsheikh E, Sylven C, Ericzon BG, Palmblad J, Mints M: Cyclic variability of
stromal cell-derived factor-1 and endothelial progenitor cells during the
menstrual cycle. Int J Mol Med 2011, 27(2):221–226.
29. Schwab KE, Chan RWS, Gargett CE: Putative stem cell activity of human
endometrial epithelial and stromal cells during the menstrual cycle. Fertil
Steril 2005, 84:1124–1130.
30. Gargett C: Uterine stem cells: what is the evidence? Hum Reprod Update
2007, 13(1):87–101.
31. Sasson IE, Taylor HS: Stem cells and the pathogenesis of endometriosis.
Ann NY Acad Sci 2008, 1127(1):106–115.
32. Kim C, Oh Y, Cho S, Chung D, Hwang J, Park K, Cho D, Choi Y, Lee B:
Increased telomerase activity and human telomerase reverse
transcriptase mRNA expression in the endometrium of patients with
endometriosis. Hum Reprod 2007, 22(3):843–849.
33. Wu JM, Wechter ME, Geller EJ, Nguyen TV, Visco AG: Hysterectomy rates in
the United States, 2003. Obstet Gynecol 2007, 110(5):1091–1095.
34. Götte M, Wolf M, Staebler A, Buchweitz O, Kelsch R, Schüring A, Kiesel L:
Increased expression of the adult stem cell marker Musashi‐1 in
endometriosis and endometrial carcinoma. J Pathol 2008, 215(3):317–329.
35. Shoae Hassani A, Mortazavi Tabatabaei SA, Sharif S, Seifalian AM, Azimi A,
Samadikuchaksaraei A, Verdi J: Differentiation of human endometrial stem
cells into urothelial cells on a three‐dimensional nanofibrous silk–
collagen scaffold: an autologous cell resource for reconstruction of the
urinary bladder wall. J Tissue Eng Regen Med 2013, [In press].36. Mayani H, Alvarado-Moreno JA, Flores-Guzmán P: Biology of human
hematopoietic stem and progenitor cells present in circulation. Arch Med
Res 2003, 34(6):476–488.
37. He Q, Wan C, Li G: Concise review: multipotent mesenchymal stromal
cells in blood. Stem Cells 2007, 25(1):69–77.
38. Robb A, Mills N, Smith I, Short A, Tura-Ceide O, Barclay G, Blomberg A,
Critchley H, Newby D, Denison F: Influence of menstrual cycle on circulating
endothelial progenitor cells. Hum Reprod 2009, 24(3):619–625.
39. Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M,
Takarada M, Sugawara I, Murakami S: Significance of immunological
detection of human telomerase reverse transcriptase: re-evaluation of
expression and localization of human telomerase reverse transcriptase.
Am J Pathol 2003, 163(3):859–867.
40. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka
S: Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 2007, 131(5):861–872.
41. Park JH, Daheron L, Kantarci S, Lee BS, Teixeira JM: Human endometrial
cells express elevated levels of pluripotent factors and are more
amenable to reprogramming into induced pluripotent stem cells.
Endocrinology 2011, 152(3):1080–1089.
42. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,
Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining
multipotent mesenchymal stromal cells. The International Society for
Cellular Therapy position statement. Cytotherapy 2006, 8(4):315–317.
43. Dimitrov R, Timeva T, Kyurkchiev D, Stamenova M, Shterev A, Kostova P,
Zlatkov V, Kehayov I, Kyurkchiev S: Characterization of clonogenic stromal
cells isolated from human endometrium. Reproduction 2008, 135(4):551–558.
44. Schwab K, Gargett C: Co-expression of two perivascular cell markers
isolates mesenchymal stem-like cells from human endometrium. Hum
Reprod 2007, 22(11):2903–2911.
45. Lynch L, Golden-Mason L, Eogan M, O’Herlihy C, O’Farrelly C: Cells with
haematopoietic stem cell phenotype in adult human endometrium:
relevance to infertility? Human Reprod 2007, 22(4):919–926.
46. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW, Orkin SH:
A protein interaction network for pluripotency of embryonic stem cells.
Nature 2006, 444(7117):364–368.
47. Ishikawa M, Nakayama K, Yeasmin S, Katagiri A, Iida K, Nakayama N, Miyazaki
K: NAC1, a potential stem cell pluripotency factor expression in normal
endometrium, endometrial hyperplasia and endometrial carcinoma. Int J
Oncol 2010, 36(5):1097–1103.
48. Sobiesiak M, Sivasubramaniyan K, Hermann C, Tan C, Örgel M, Treml S,
Cerabona F, de Zwart P, Ochs U, Müller CA: The mesenchymal stem cell
antigen MSCA-1 is identical to tissue non-specific alkaline phosphatase.
Stem Cells Dev 2009, 19(5):669–677.
49. Krusche CA, Kroll T, Beier HM, Classen-Linke I: Expression of leucine-rich
repeat-containing G-protein-coupled receptors in the human cyclic
endometrium. Fertil Steril 2007, 87(6):1428–1437.
50. Gil Sanchis C, Cervelló I, Mas A, Faus A, Pellicer A, Simón C: Leucine-rich
repeat-containing G-protein-coupled receptor 5 (Lgr5) as a putative
human endometrial stem cell marker. Mol Hum Reprod 2013, 19(7):407–414.
51. Masuda H, Anwar SS, Bühring H-J, Rao JR, Gargett CE: A novel marker of
human endometrial mesenchymal stem-like cells. Cell Transplant 2012,
21(10):2201–2214.
52. Awong G, Herer E, Surh CD, Dick JE, La Motte-Mohs RN, Zúñiga-Pflücker JC:
Characterization in vitro and engraftment potential in vivo of human
progenitor T cells generated from hematopoietic stem cells. Blood 2009,
114(5):972–982.
53. Peron J, Jazedje T, Brandao W, Perin P, Maluf M, Evangelista L, Halpern S,
Nisenbaum M, Czeresnia C, Zatz M: Human endometrial-derived
mesenchymal stem cells suppress inflammation in the central nervous
system of EAE mice. Stem Cell Rev 2012, 8(3):940–952.
54. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC: Suppression of
allogeneic T-cell proliferation by human marrow stromal cells:
implications in transplantation. Transplantation 2003, 75(3):389–397.
55. Kiss J, Urban V, Dudics V, Vas V: Uher F: [Mesenchymal stem cells and the
immune system–immunosuppression without drugs?]. Orv Hetil 2008,
149(8):339–346.
56. Pisati F, Belicchi M, Acerbi F, Marchesi C, Giussani C, Gavina M, Javerzat S,
Hagedorn M, Carrabba G, Lucini V: Effect of human skin-derived stem cells
on vessel architecture, tumor growth, and tumor invasion in brain tumor
animal models. Cancer Res 2007, 67(7):3054–3063.
Verdi et al. Journal of Biological Engineering 2014, 8:20 Page 10 of 10
http://www.jbioleng.org/content/8/1/2057. Ehtesham M, Kabos P, Kabosova A, Neuman T, Black KL, John SY: The use of
interleukin 12-secreting neural stem cells for the treatment of intracranial
glioma. Cancer Res 2002, 62(20):5657–5663.
58. Ehtesham M, Kabos P, Gutierrez MA, Chung NH, Griffith TS, Black KL, John
SY: Induction of glioblastoma apoptosis using neural stem cell-mediated
delivery of tumor necrosis factor-related apoptosis-inducing ligand.
Cancer Res 2002, 62(24):7170–7174.
59. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J,
Hentschel S, Vecil G, Dembinski J: Human bone marrow–derived
mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005,
65(8):3307–3318.
60. Han X, Meng X, Yin Z, Rogers A, Zhong J, Rillema P, Jackson JA, Ichim TE,
Minev B, Carrier E: Inhibition of intracranial glioma growth by
endometrial regenerative cells. Cell Cycle 2009, 8(4):606–610.
61. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD: Dkk-1 secreted by mesenchymal
stem cells inhibits growth of breast cancer cells < i > via</i > depression
of Wnt signalling. Cancer Lett 2008, 269(1):67–77.
62. Qiao L, Zhao TJ, Wang FZ, Shan CL, Ye LH, Zhang XD: NF-kappaB
downregulation may be involved the depression of tumor cell
proliferation mediated by human mesenchymal stem cells. Acta
Pharmacol Sin 2008, 29(3):333–340.
63. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999,
284(5411):143–147.
64. Colter DC, Class R, DiGirolamo CM, Prockop DJ: Rapid expansion of
recycling stem cells in cultures of plastic-adherent cells from human
bone marrow. Proc Natl Acad Sci U S A 2000, 97(7):3213–3218.
65. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz
HP, Hedrick MH: Multilineage cells from human adipose tissue:
implications for cell-based therapies. Tissue Eng 2001, 7(2):211–228.
66. Cho NH, Park YK, Kim YT, Yang H, Kim SK: Lifetime expression of stem cell
markers in the uterine endometrium. Fertil and Steril 2004, 81(2):403–407.
67. Gargett CE, Chan RW, Schwab KE: Endometrial stem cells. Curr Opin Obstet
Gynecol 2007, 19(4):377–383.
68. Kao AP, Wang KH, Chang CC, Lee JN, Long CY, Chen HS, Tsai CF, Hsieh TH,
Tsai EM: Comparative study of human eutopic and ectopic endometrial
mesenchymal stem cells and the development of an in vivo
endometriotic invasion model. Fertil Steril 2011, 95(4):1308–1315. e1301.
69. Hong I-S, Kim S-H, Koong MK, Jun JH, Kim S-H, Lee Y-S, Kang K-S: Roles of
p38 and c-jun in the differentiation, proliferation and immortalization of
normal human endometrial cells. Hum Reprod 2004, 19(10):2192–2199.
70. Giudice A, Trounson A: Genetic modification of human embryonic stem
cells for derivation of target cells. Cell Stem Cell 2008, 2(5):422–433.
71. Wang H, Jin P, Sabatino M, Ren J, Civini S, Bogin V, Ichim TE, Stroncek DF:
Comparison of endometrial regenerative cells and bone marrow stromal
cells. J Transl Med 2012, 10(1):207.
72. Kazemnejad S, Akhondi M-M, Soleimani M, Zarnani AH, Khanmohammadi
M, Darzi S, Alimoghadam K: Characterization and chondrogenic
differentiation of menstrual blood-derived stem cells on a nanofibrous
scaffold. Int J Artif Organs 2012, 35(1):55–66.
73. Gluckman E, Broxmeyer H, Auerbach AD, Friedman HS, Douglas GW,
Devergie A, Esperou H, Thierry D, Socie G, Lehn P: Hematopoietic
reconstitution in a patient with Fanconi’s anemia by means of
umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989,
321(17):1174–1178.
74. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC: Human
bone marrow stem cells exhibit neural phenotypes and ameliorate
neurological deficits after grafting into the ischemic brain of rats.
Exp Neurol 2002, 174(1):11–20.
75. Meletis K, Frisen J: Have the bloody cells gone to our heads? J Cell Biol
2001, 155(5):699–702.
76. Hakuno D, Fukuda K, Makino S, Konishi F, Tomita Y, Manabe T, Suzuki Y,
Umezawa A, Ogawa S: Bone marrow–derived regenerated
cardiomyocytes (CMG cells) express functional adrenergic and
muscarinic receptors. Circulation 2002, 105(3):380–386.
77. Wakitani S, Saito T, Caplan AI: Myogenic cells derived from rat bone
marrow mesenchymal stem cells exposed to 5‐azacytidine. Muscle Nerve
1995, 18(12):1417–1426.
78. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic
tissues. Science 1997, 276(5309):71–74.79. Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM, Krause DS:
Derivation of hepatocytes from bone marrow cells in mice after
radiation‐induced myeloablation. Hepatology 2000, 31(1):235–240.
80. Theise ND, Nimmakayalu M, Gardner R, Illei PB, Morgan G, Teperman L,
Henegariu O, Krause DS: Liver from bone marrow in humans. Hepatol
2000, 32(1):11–16.
81. Wexler SA, Donaldson C, Denning Kendall P, Rice C, Bradley B, Hows JM:
Adult bone marrow is a rich source of human mesenchymal ‘stem’cells
but umbilical cord and mobilized adult blood are not. Br J Haematol
2003, 121(2):368–374.
82. Murphy MP, Wang H, Patel AN, Kambhampati S, Angle N, Chan K, Marleau
AM, Pyszniak A, Carrier E, Ichim TE, Riordan NH: Allogeneic endometrial
regenerative cells: an “Off the shelf solution” for critical limb ischemia?
J Transl Med 2008, 6:45.
83. Hida N, Nishiyama N, Miyoshi S, Kira S, Segawa K, Uyama T, Mori T, Miyado
K, Ikegami Y, Cui C: Novel Cardiac Precursor‐Like Cells from Human
Menstrual Blood‐Derived Mesenchymal Cells. Stem Cells 2008,
26(7):1695–1704.
84. Ulrich D, Edwards SL, White JF, Supit T, Ramshaw JA, Lo C, Rosamilia A,
Werkmeister JA, Gargett CE: A preclinical evaluation of alternative
synthetic biomaterials for fascial defect repair using a rat abdominal
hernia model. PLoS One 2012, 7(11):e50044.
85. Edwards SL, Werkmeister JA, Rosamilia A, Ramshaw JA, White JF, Gargett CE:
Characterisation of clinical and newly fabricated meshes for pelvic organ
prolapse repair. J Mech Behav Biomed Mater 2013, 23:53–61.
86. Shoae-Hassani A, Sharif S, Seifalian AM, Mortazavi-Tabatabaei SA, Rezaie S,
Verdi J: Endometrial stem cell differentiation into smooth muscle cell: a
novel approach for bladder tissue engineering in women. BJU Int 2013,
112(6):854–863.
87. Borlongan CV, Kaneko Y, Maki M, Yu S-J, Ali M, Allickson JG, Sanberg CD,
Kuzmin-Nichols N, Sanberg PR: Menstrual blood cells display stem cell-like
phenotypic markers and exert neuroprotection following transplantation
in experimental stroke. Stem Cells Dev 2010, 19(4):439–452.
88. Zhong Z, Patel AN, Ichim TE, Riordan NH, Wang H, Min W-P, Woods EJ, Reid
M, Mansilla E, Marin GH: Feasibility investigation of allogeneic endometrial
regenerative cells. J Transl Med 2009, 7(15):29–37.
89. Ichim TE, Alexandrescu DT, Solano F, Lara F, Campion RDN, Paris E, Woods
EJ, Murphy MP, Dasanu CA, Patel AN: Mesenchymal stem cells as anti-
inflammatories: implications for treatment of Duchenne muscular
dystrophy. Cell Immunol 2010, 260(2):75–82.
90. Ichim TE, Solano F, Lara F, Rodriguez JP, Cristea O, Minev B, Ramos F,
Woods EJ, Murphy MP, Alexandrescu DT, Patel AN, Riordan NH:
Combination stem cell therapy for heart failure. Int Arch Med 2010, 3(1):5.
91. Tosh D, Slack JM: How cells change their phenotype. Nat Rev Mol Cell Biol
2002, 3(3):187–194.
92. Du H, Taylor HS: Contribution of Bone Marrow‐Derived Stem Cells to
Endometrium and Endometriosis. Stem Cells 2007, 25(8):2082–2086.
93. Du H, Taylor HS: Reviews: stem cells and female reproduction. Reprod Sci
2009, 16(2):126–139.
94. Polyak K, Weinberg RA: Transitions between epithelial and mesenchymal
states: acquisition of malignant and stem cell traits. Nature Rev Cancer
2009, 9(4):265–273.
95. Starzinski-Powitz A, Zeitvogel A, Schreiner A, Baumann R: In search of
pathogenic mechanisms in endometriosis: the challenge for molecular
cell biology. Curr Mol Med 2001, 1(6):655–664.
96. Bockeria L, Bogin V, Bockeria O, Le T, Alekyan B, Woods EJ, Brown AA, Ichim
TE, Patel AN: Endometrial regenerative cells for treatment of heart failure:
a new stem cell enters the clinic. J Transl Med 2013, 11:56.
doi:10.1186/1754-1611-8-20
Cite this article as: Verdi et al.: Endometrial stem cells in regenerative
medicine. Journal of Biological Engineering 2014 8:20.
